Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, inaugurated on Monday its new office in Cairo.

"The company has had a presence in Egypt through a scientific office, and its new office marks the launch of its new commercial legal entity in the country, and marks an important milestone in Boehringer Ingelheim’s longstanding history in Egypt. In addition, it is a reflection of the country’s robust infrastructure, accessibility and central regional prominence," the company said in a statement.

Boehringer Ingelheim’s general manager and head of human pharma for Egypt and the Levant, Iraq, and Near East Africa Yasser Farghali said that the launch of the new office and second legal entity marks a new chapter in the company's journey in Egypt, which began in 1961.

"The opening of our new office mirrors the continued upward growth strategy the country is experiencing by providing a strategic platform for expanding access to our key therapeutic innovations in human and animal health. It will further harness the recent economic and regulatory reforms that are benefitting the entire healthcare ecosystem to support the neighbouring region," he added.

“Egypt is a crucial market in the region, and an important hub in our global network. We are focused on delivering international best practices, innovative medical trends, while also ramping up our research and development capabilities, to address the diverse needs of patients in the country and region. The future is promising," Farghali said.

"Egypt represents a cornerstone in Boehringer Ingelheim’s operations. The company’s story, which began more than five decades ago, has evolved into sheer dedication towards building a robust business that is in line with the country’s strong infrastructure, accessibility and central regional prominence," he said.

Some of the key notable achievements of Boehringer Ingelheim in Egypt include its Angel’s Initiative, which aims to improve and maintain the quality of existing stroke centres together with the local medical community, according the statement.

The company said that the Angel’s Initiative is focused on building a network of no less than 500 stroke centres to improve care management protocols.

In human health, Boehringer Ingelheim is planning to launch further initiatives in Egypt to complement its current portfolio and help people living with type 2 diabetes live healthier and safer lives.

In animal health, the company supplies more than 11 percent of the Egyptian market's animal health vaccination needs and solutions.